Baseline characteristics of 608 patients with PsA treated with SEC in the period September 2016–March 2020
| PsA features | Total patients | Group A | Group B | P value |
| Male sex (n, %) | 251 (41.28%) | 98 (43.17%) | 153 (40.16%) | ns |
| Age (years), mean (SD) | 52.78 (11.33) | 50.09 (12.01) | 54.38 (10.60) | ns |
| Age of diagnosis (years), mean (SD) | 44.73 (11.50) | 44.75 (11.72) | 44.71 (11.39) | ns |
| Age of disease onset (years), mean (SD) | 41.97 (13.66) | 40.52 (15.86) | 42.83 (12.11) | ns |
| Disease duration (years), mean (SD) | 9.49 (6.85) | 6.69 (5.69) | 11.17 (6.94) | 0.01 |
| PsA (n, %) | 608 | 227 (37.34%) | 381 (62.67%) | NA |
| Polyarticular | 363 (59.70%) | 128 (56.39%) | 235 (61.68%) | 0.04 |
| Monoarticular/Oligoarticular | 163 (26.81%) | 74 (32.60%) | 89 (23.36%) | ns |
| Axial | 146 (24.01%) | 48 (21.15%) | 98 (25.72%) | 0.02 |
| Only involvement DIP | 9 (1.48%) | 3 (1.32%) | 6 (1.57%) | ns |
| Mutilating arthritis | 3 (0.49%) | 0 (0%) | 3 (0.79%) | ns |
| Enthesitis | 264 (43.42%) | 100 (44.05%) | 164 (43.04%) | ns |
| Dactylitis | 97 (15.95%) | 33 (14.54%) | 64 (16.80%) | 0.05 |
| Psoriasis, n (%) | 418 (68.75%) | 156 (68.72%) | 262 (68.77%) | ns |
| Age of psoriasis onset (years), mean (SD) | 23.60 (19.70) | 27.53 (18.15) | 35.15 (13.78) | 0.04 |
| Onychopathy, n (%) | 222 (36.51%) | 82 (36.12%) | 140 (36.75%) | ns |
| IBD, n (%) | 11 (1.81%) | 1 (0.44%) | 10 (2.62%) | 0.05 |
| Uveitis, n (%) | 25 (4.11%) | 14 (6.17%) | 11 (2.89%) | 0.02 |
| Familiarity with psoriasis or PsA | 184 (30.26%) | 70 (30.84%) | 114 (29.92%) | ns |
| Erosions, n (%) | 174 (28.62%) | 45 (19.82%) | 129 (33.86%) | 0.04 |
| Weight (kg), mean (SD) | 73.77 (15.41) | 70.09 (15.99) | 73.98 (15.09) | ns |
| Height (cm), mean (SD) | 166.77 (13.19) | 167.58 (13.78) | 166.27 (12.81) | ns |
| BMI, mean (SD) | 26.19 (5.19) | 25.85 (4.88) | 26.39 (5.37) | ns |
| TJ [0–68], mean (SD) | 8.02 (6.82) | 8.20 (6.71) | 7.91 (6.88) | ns |
| SJ [0–66], mean (SD) | 2.25 (2.82) | 2.19 (2.87) | 2.28 (2.79) | ns |
| LEI [0–6], mean (SD) | 1.62 (1.83) | 1.91 (1.92) | 1.44 (1.76) | ns |
| Dactylitis [0–20] number digit, mean (SD) | 0.28 (1.27) | 0.22 (0.83) | 0.31 (1.48) | ns |
| PASI [0–72], mean (SD) | 4.24 (7.38) | 4.06 (7.09) | 4.34 (7.54) | ns |
| ESR [0–25] [mm/hour), mean (SD) | 21.13 (17.08) | 21.24 (19.32) | 21.24 (19.32) | ns |
| CRP [0–6] [mg/L), mean (SD) | 6.45 (9.82) | 6.01 (9.14) | 6.01 (9.14) | ns |
| DAPSA [0–164], mean (SD) | 25.29 (11.14) | 25.24 (10.91) | 25.36 (11.31) | ns |
| ASDAS [0–6], mean (SD) | 3.26 (2.88) | 3.50 (4.59) | 3.12 (0.99) | ns |
| HAQ-S [0–8], mean (SD) | 1.28 (8.23) | 1.11 (0.74) | 1.39 (0.87) | ns |
| VAS-pain [0–10], mean (SD) | 6.70 (1.67) | 6.62 (1.73) | 6.76 (1.65) | ns |
| VAS-gh [0–10], mean (SD) | 6.71 (4.93) | 5.89 (1.64) | 7.01 (6.08) | ns |
| BASDAI [0–10], mean (SD) | 5.22 (2.17) | 5.23 (2.08) | 5.21 (2.22) | ns |
| BASFI [0–10], mean (SD) | 5.17 (2.14) | 5.02 (2.18) | 5.26 (2.12) | ns |
| Mean treatment duration (months), mean (SD) | 18.77 (11.17) | 18.50 (10.76) | 18.93 (11.42) | ns |
| Dosage 300 mg/injection (n, %) | 334 (54.93%) | 40 (17.62%) | 294 (77.17%) | 0.01 |
| Dosage 150 mg/injection (n, %) | 274 (45.07%) | 187 (82.38%) | 87 (22.83%) | 0.01 |
| First line (n, %) | 227 (37.34%) | 227 (100%) | 0 (0%) | NA |
| Failure biological drugs (n, %) | 381 (62.67%) | 0 (0%) | 381 (100%) | NA |
| Second line (n, %) | 149 (24.51%) | 0 (0%) | 149 (39.11%) | NA |
| Third line (n, %) | 114 (18.75%) | 0 (0%) | 114 (29.92%) | NA |
| Fourth line (n, %) | 73 (12.01%) | 0 (0%) | 73 (19.16%) | NA |
| Fifth line (n, %) | 26 (4.27%) | 0 (0%) | 26 (8.82%) | NA |
| Sixth line (n, %) or more | 19 (3.13%) | 0 (0%) | 19 (4.49%) | NA |
| Concomitant NSAIDs, n (%) | 314 (51.64%) | 120 (52.86%) | 194 (50.92%) | ns |
| Concomitant glucocorticosteroid, n (%) | 162 (26.64%) | 32 (14.10%) | 130 (34.12%) | 0.03 |
| Concomitant csDMARDs, n (%) | 256 (42.11%) | 97 (42.73%) | 159 (41.73%) | ns |
| Methotrexate | 202 (33.22%) | 80 (35.24%) | 122 (32.02%) | ns |
| Sulphasalazine | 44 (7.24%) | 20 (8.81%) | 24 (6.23%) | ns |
| Leflunomide | 28 (4.61%) | 8 (3.52%) | 20 (5.25%) | ns |
| Hydroxychloroquine | 9 (1.48%) | 3 (1.32%) | 6 (1.57%) | ns |
| Ciclosporin | 6 (0.99%) | 1 (0.44%) | 5 (1.31%) | ns |
Data are expressed as mean (SD) unless otherwise specified; range of possible values are indicated in square brackets. p≤0.05. Values were computed by means of a χ2 test (for proportion) or Wilcoxon’s test (for continuous data).
The italics character is used to mark p value; the bold is used to highlight the number (percentage) of total patients and of subgroups.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, body mass index; CRP, C reactive protein; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAPSA, Disease Activity Index for Psoriatic Arthritis; DIP, distal interphalangeal joints; ESR, erythrocyte sedimentation rate; Group A, naïve to TNF inhibitors; Group B, TNF inhibitors and IL-12/23 inhibitors failure; HAQ-S, Health Assessment Questionnaire modified for spondyloarthritis; IBD, inflammatory bowel disease; LEI, Leeds Enthesitis Index; NA, not applicable; ns, not statistically significant; NSAIDs, non-steroidal inflammatory drugs; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; SJ, swollen joint; TJ, tender joint; TNF, tumour necrosis factor.